Mr. Thomas Smeenk reports
PETER LACEY INCREASES HIS INVESTMENT IN HEMOSTEMIX INC.
Further to the June 11, 2021, news release and pursuant to the closing of the offering of debenture units of Hemostemix Inc., Peter Lacey, a director and chair of Hemostemix, acquired 2,500 debenture units. Each debenture unit consisted of a $1,000 principal amount debenture and 2,500 common share purchase warrants. The principal amount of the debentures may be convertible, only at the option of the company (and not at the option of the holder), into common shares of the company at a price of 40 cents per common share. Each debenture warrant entitles the holder to acquire one common share at a price of 55 cents per common share until June 10, 2023, subject to accelerated expiry provisions. Prior to the offering, Mr. Lacey held 4,491,891 common shares, or approximately 7.80 per cent of the total issued and outstanding common shares. Mr. Lacey also held 4.5 million common share purchase warrants and 555,000 stock options. Mr. Lacey now controls 4,491,891 common shares, or approximately 7.80 per cent of the total issued and outstanding common shares, the debenture in the principal amount of $2.5-million, 10.75 million common share purchase warrants (including the debenture warrants) and 555,000 stock options. Assuming the conversion of the debenture and the exercise of the common share purchase warrants (including the debenture warrants) and the stock options, Mr. Lacey would own or control 22,046,891 common shares, or approximately 29.35 per cent of the total issued and outstanding common shares. The acquisition of the debenture units by Mr. Lacey was made for investment purposes. Mr. Lacey may increase or decrease his investment in Hemostemix depending on market conditions or any other relevant factors.
About Hemostemix Inc.
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum technology pioneer award, the company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On Oct. 21, 2019, the company announced the results from its phase 2 CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years. The company owns 91 patents across five patent families.
© 2021 Canjex Publishing Ltd. All rights reserved.